ROBIN OligoMET Center: Radiation and Biology Insights for Prostate Cancer Metastasis
Official title: Radiation Oncology-Biology Integration Network on Oligometastasis (ROBIN OligoMET) Center
Funded at University of Maryland Baltimore · NIH-11358355 · Data updated 2026-11-12
A nationwide collaboration is testing how targeted radiation can alter the spread of prostate cancer that has few metastases, with the goal of improving control of the disease.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Maryland Baltimore NIH-funded |
| Lab location | 1 site (Baltimore, United States) |
| Project start | August 4, 2022 |
| Project end | July 31, 2027 |
| Funding year | 2026 |
| Award (this year) | $1,503,345 |
| NIH project number | 5U54CA273956-05 |
| Project ID | NIH-11358355 on NIH RePORTER |
Who could benefit from this research
✓Could help
Adults with de novo oligometastatic prostate cancer who are eligible for radiation consolidation strategies and participate in translational studies.
✕Less likely to help
Patients not meeting criteria for oligometastatic disease or not suitable for radiation consolidation may not experience direct benefit.
What this research studies
This center brings together leading experts from UM, Weill Cornell, and TJU to study how radiation therapy may influence the biology of metastasis in de novo oligometastatic prostate cancer. By combining clinical trials, tumor profiling, and computational analyses, the project aims to reveal mechanisms by which radiation could reduce metastatic progression. The work will translate findings into new strategies for using radiation to manage limited metastatic deposits and potentially alter disease course. Participants would contribute tumor samples, imaging, and clinical data as part of integrated studies.
Why it matters
Potential benefit: If successful, patients with oligometastatic prostate cancer could benefit from more effective radiation strategies that delay progression and improve quality of life.
How similar studies have gone: Preliminary randomized studies in recurrent oligometastatic settings support potential benefits of RT consolidation, with ongoing exploration in the de novo space.
Where this research is happening
-
University of Maryland Baltimore
Baltimore, United States Active
Researchers
- Principal investigator: Sawant, Amit — University of Maryland Baltimore
- Study coordinator: Sawant, Amit
Related research
Other NIH-funded projects on the same topics.
-
Understanding Radiation for Prostate Cancer with Limited Spread
This research brings together experts to learn how radiation therapy can help patients with prostate cancer that has spread to only a few spots.
-
Investigating how radiation therapy can improve treatment for limited metastatic prostate cancer.
This study is looking at how radiation therapy can help men with prostate cancer that has spread to a few places in the body, aiming to see if it can stop the cancer from getting worse and improve treatment options for patients.
-
Adding targeted stereotactic body radiation therapy to standard systemic treatment for people with oligometastatic urothelial (bladder) carcinoma.
This study will test whether adding stereotactic body radiation therapy (SBRT) to usual systemic treatment helps people with urothelial (bladder) cancer who have up to three extracranial metastases.
-
Stereotactic body radiotherapy for extracranial oligometastatic breast cancer
This project sees if stereotactic body radiotherapy (SBRT) helps control cancer and extend survival in adults with extracranial oligometastatic breast cancer.
-
Stereotactic body radiotherapy (SABR) for limited metastases
This program tries stereotactic body radiotherapy (SABR) in people with up to five oligometastatic or oligoprogressive cancer lesions to see if it controls disease better, affects symptoms and side effects, and changes ctDNA in the blood.
-
Immediate simulation-free SBRT for people with up to five metastatic tumors
This tests whether giving stereotactic body radiation therapy (SBRT) right away without a separate CT simulation helps people with up to five metastatic cancer spots get treatment faster.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.